The Consumer Drug Transparency Act establishes clear guidelines to enhance transparency in the pharmaceutical industry. Under this act, pharmacists, pharmaceutical companies, and insurance carriers are prohibited from entering into contractual agreements that prevent pharmacists from informing patients about the potential cost savings associated with paying cash for medications rather than using their health insurance plans.
Furthermore, the act could be strengthened by introducing additional measures or regulations. For instance, implementing penalties and civil damages awards in cases where fraudulent practices or prescription price gouging are identified would serve as a deterrent and promote accountability within the industry. Such measures would help ensure that consumers are protected and can make informed decisions regarding their medication costs.